The Future of Health Technology Assessment (HTA) in Greece: Trends and Predictions

By Staff Writer

October 22, 2023

Greek Healthcare System

The Greek healthcare system is a unique blend of both public and private sectors. The National Organisation for the Provision of Health Services (EOPYY), established in 2011, is the sole purchaser of healthcare services for patients covered by the publicly financed National Health System (ESY). The Ministry of Health (MoH) is responsible for planning and regulating the ESY, and setting up regional health authorities (YPEs) that carry out extensive healthcare planning, organisation, and provision.

The introduction of the HTA framework in Greece in 2018 was a significant step forward towards evidence-based resource allocation decisions. It has improved patient access to innovative therapies at affordable prices and in a timely manner. Since its establishment, a significant improvement in the performance of the HTA process has been observed. The backlog of medicinal products has decreased, as well as the time of HTA clinical assessment.

However, the current HTA process in Greece does not include medical devices. This creates significant uncertainty for the providers of medical devices and pharmaceutical companies. A Committee for the Negotiation of Medical Devices’ Fees and Prices does exist, but it is not involved in the assessment of new technologies. It only negotiates the prices of technologies that either already exist in the market or are imported through ad hoc decisions.

There is strong consensus that the creation of a national decisive and legally binding HTA organisation, which will be independent of the MoH, both administratively and financially, might be more credible and effective. Another next step would be the inclusion of assessment and negotiation procedures for medical devices under an HTA organisation. This would help streamline the process and increase efficiency in the healthcare system.

Reference url

Recent Posts

lenacapavir HIV prevention
      

Lenacapavir HIV Prevention: Approval and Access Strategy Updates

🌍 *Could a twice-yearly shot revolutionize HIV prevention?*
Gilead Sciences has submitted key applications to the EMA for lenacapavir, a groundbreaking HIV-1 capsid inhibitor designed for use as pre-exposure prophylaxis (PrEP). With promising trial results indicating a significant reduction in HIV infections, this innovation could enhance adherence to prevention strategies globally. Discover more about this game-changing development!

#SyenzaNews #globalhealth #healthcareInnovation

Africa health partnership
      

Strengthening Africa Health Partnership

🌍 Can collaboration redefine Africa’s health landscape?

A newly signed Memorandum of Understanding between Africa CDC and Global Health EDCTP3 promises to enhance health research, clinical trials, and pandemic preparedness on the continent. With a focus on training, local manufacturing, and equitable partnerships, this initiative aims to address pressing global health challenges while improving health outcomes across Africa.

Look into the details of this transformative partnership and its implications for the future of healthcare in the region!

#SyenzaNews #globalhealth #HealthcareInnovation

breast cancer Africa
    

Urgent Call for Enhanced Breast Cancer Africa Control Measures

🚨 Are we doing enough to tackle the imminent breast cancer crisis in Africa?

A recent WHO report reveals alarming trends, predicting that 135,000 women could succumb to breast cancer by 2040 unless urgent actions are taken. The report highlights critical gaps in healthcare infrastructure and capacity, emphasizing the need for investment in screening programs and professional training to improve outcomes across the continent.

Review the full article to explore the necessary steps towards reinforcing breast cancer control measures in Africa.

#SyenzaNews #globalhealth #oncology #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.